Jie Dai

3.2k citations

98 papers · 1.8k indexed · h-index 26

Oncology top 2%
- Cutaneous Melanoma Detection and Management 35
- CAR-T cell therapy research 22
- Cancer Immunotherapy and Biomarkers 13
Immunology top 10%
- Immunotherapy and Immune Responses 10
Cancer Research top 10%
- Cancer Genomics and Diagnostics 8
Molecular Biology top 10%
- Melanoma and MAPK Pathways 30
Pulmonary and Respiratory Medicine top 10%
- Renal cell carcinoma treatment 10
Genetics
- Virus-based gene therapy research 6

Co-authors: Lu Si Xinan Sheng Chuanliang Cui Jun Guo Zhihong Chi Yan Kong Bin Lian Xue Bai
Cited by: Oncology Immunology Cancer Research
Journals: Journal of Clinical Investigation (1 paper)Journal of Clinical Oncology (22 papers)ACS Nano (1 paper)
Partner nations: China United States Ethiopia

In The Last Decade

Jie Dai

96 papers receiving 1.7k citations

Peers

Countries citing papers authored by Jie Dai

Since Specialization

Citations

This map shows the geographic impact of Jie Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jie Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jie Dai more than expected).

Fields of papers citing papers by Jie Dai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jie Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jie Dai. The network helps show where Jie Dai may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jie Dai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jie Dai Line = papers co-authored together Jie Dai links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis Clinical and Translational Medicine ·Jie Dai,Tianxiao Xu,Lifeng Li,Meiyu Fang,Jing Lin,Jun Cao,Xue Bai,Caili Li,Xiaoting Wei,Junjie Gu,Yaoyao Liu,Xuan Gao,Xuefeng Xia,Jun Guo,Yu Chen,Lili Mao,Lu Si	2025	1
2	Tucidinostat plus toripalimab in patients with unresectable or metastatic melanoma: An open-label, single-arm phase II study. Journal of Clinical Oncology ·Lili Mao,Jie Dai,Xue Bai,Yan Kong,Xinan Sheng,Zhihong Chi,Chuanliang Cui,Bin Lian,Bixia Tang,Xieqiao Yan,Xuan Wang,Siming Li,Li Zhou,Xiaoting Wei,Juan Li,Caili Li,Rong Duan,Huayan Xu,Jun Guo,Lu Si	2024	1
3	Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications Cancer Research Communications ·Jie Dai,Jia Jia,Fanshuang Zhang,Kaihua Liu,Yanfeng Xi,Pei Yuan,Lili Mao,Xue Bai,Xiaoting Wei,Bingning Wang,Jiangtao Li,Yang Xu,Ting Liu,Shuang Chang,Yang Shao,Jun Guo,Jianming Ying,Lu Si	2024	2
4	Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single‐cell transcriptomic analysis: Implications for distinct immunotherapy outcomes The Journal of Gene Medicine ·Xinyun Fang,Dianke Li,Shiyue Wan,Junjie Hu,Peng Zhang,Jie Dai,Linsong Chen,Gening Jiang,Nan Song	2024	5
5	Pembrolizumab Versus High-Dose Interferon-α2b as Adjuvant Therapy for Pediatric Melanoma: A Retrospective Study Dermatology Practical & Conceptual ·Yu Du,Zhonghui Qi,Xianbin Liang,Jie Dai,Xiaoting Wei,Xue Bai,Lili Mao,Zhihong Chi,Chuanliang Cui,Bin Lian,Bixia Tang,Xuan Wang,Yu Chen,Jun Guo,Lu Si	2024	1
6	Neoadjuvant pembrolizumab and lenvatinib in resectable mucosal melanoma: NeoPlus study update. Journal of Clinical Oncology ·Lili Mao,Jie Dai,Xue Bai,Yan Kong,Chuanliang Cui,Zhihong Chi,Xinan Sheng,Bin Lian,Bixia Tang,Xieqiao Yan,Xuan Wang,Siming Li,Li Zhou,Xiaoting Wei,Juan Li,Caili Li,Xiaowen Wu,Jun Guo,Lu Si	2024	2
7	OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study Journal for ImmunoTherapy of Cancer ·Chuanliang Cui,Xuan Wang,Bin Lian,Qing Ji,Li Zhou,Zhihong Chi,Lu Si,Xinan Sheng,Yan Kong,Jiayi Yu,Siming Li,Lili Mao,Bixia Tang,Jie Dai,Xieqiao Yan,Xue Bai,Robert H.I. Andtbacka,Jun Guo	2022	38
8	Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis Journal for ImmunoTherapy of Cancer ·Siming Li,Xiaowen Wu,Xieqiao Yan,Li Zhou,Zhihong Chi,Lu Si,Chuanliang Cui,Bixia Tang,Lili Mao,Bin Lian,Xuan Wang,Xue Bai,Jie Dai,Yan Kong,Xiongwen Tang,Hui Feng,Sheng Yao,Keith T. Flaherty,Jun Guo,Xinan Sheng	2022	33
9	Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial Annals of Oncology ·Bin Lian,Lu Si,Z.H. Chi,Xinan Sheng,Yan Kong,X. Wang,Hui Tian,Kaiquan Li,Li Mao,Xue Bai,B.X. Tang,Xieqiao Yan,S.M. Li,Li Zhou,Jie Dai,Xiongwen Tang,Fei-Wu Ran,Sheng Yao,Jun Guo,C. Cui	2022	27
10	EZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma Journal of Investigative Dermatology ·Tianxiao Xu,Jie Dai,Lirui Tang,Lu Yang,Lu Si,Xinan Sheng,Chuanliang Cui,Zhihong Chi,Yan Kong,Jun Guo	2021	26
11	Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma Journal of Clinical Oncology ·Xieqiao Yan,Xinan Sheng,Zhihong Chi,Lu Si,Chuanliang Cui,Yan Kong,Bixia Tang,Lili Mao,Xuan Wang,Bin Lian,Siming Li,Xue Bai,Li Zhou,Jie Dai,Hong Yao,Jun Guo	2021	36
12	cMET-N375S germline mutation is associated with poor prognosis of melanoma in Chinese patients Translational Cancer Research ·Tianxiao Xu,Sifan Yu,Meng Ma,Jie Dai,Zhihong Chi,Lu Si,Xinan Sheng,Chuanliang Cui,Yan Kong,Jun Guo	2018	1
13	Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study European Journal of Cancer ·Xinan Sheng,Dengfeng Cao,Jianlin Yuan,Fangjian Zhou,Qiang Wei,Xiaodong Xie,Chuanliang Cui,Zhihong Chi,Lu Si,Siming Li,Lili Mao,Bin Lian,Bixia Tang,Xieqiao Yan,Xuan Wang,Yan Kong,Jie Dai,Xue Bai,Li Zhou,Jun Guo	2018	37
14	Gene expression screening identifies CDCA5 as a potential therapeutic target in acral melanoma Human Pathology ·Tianxiao Xu,Meng Ma,Jie Dai,Sifan Yu,Xiaowen Wu,Huan Tang,Jiayi Yu,Junya Yan,Huan Yu,Zhihong Chi,Lu Si,Xinan Sheng,Chuanliang Cui,Yan Kong,Jun Guo	2018	8
15	MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases Clinical Cancer Research ·Xue Bai,Yan Kong,Zhihong Chi,Xinan Sheng,Chuanliang Cui,Xuan Wang,Lili Mao,Bixia Tang,Siming Li,Bin Lian,Xieqiao Yan,Li Zhou,Jie Dai,Jun Guo,Lu Si	2017	72
16	Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma Oncology Letters ·Xiaowen Wu,Junya Yan,Jie Dai,Meng Ma,Huan Tang,Jiayi Yu,Tianxiao Xu,Huan Yu,Lu Si,Zhihong Chi,Xinan Sheng,Chuanliang Cui,Yan Kong,Jun Guo	2017	24
17	Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors Clinical Cancer Research ·Yan Kong,Lu Si,Yiqian Li,Xiaowen Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chi,Xinan Sheng,Chuanliang Cui,Jun Guo	2015	58
18	Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib Clinical Cancer Research ·Jie Dai,Yan Kong,Lu Si,Zhihong Chi,Chuanliang Cui,Xinan Sheng,Lili Mao,Siming Li,Bin Lian,Ruifeng Yang,Shujing Liu,Xiaowei Xu,Jun Guo	2013	38
19	Antinociceptive effects of intrathecally administered huwentoxin-I, a selective N-type calcium channel blocker, in the formalin test in conscious rats Toxicon ·Jiaqin Chen,Yong-Quen Zhang,Jie Dai,Zhuo-Min Luo,Songping Liang	2004	26
20	A Pilot Study on Anticancer Activities of Chinese Leek The Journal of Alternative and Complementary Medicine ·Jun Shao,Jie Dai,Joseph K.H.	2001	8

About Jie Dai

Jie Dai is a scholar working on Oncology, Immunology and Molecular Biology, having authored 98 papers that have together received 1.8k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (35 papers), Melanoma and MAPK Pathways (30 papers), CAR-T cell therapy research (22 papers), Cancer Immunotherapy and Biomarkers (13 papers), Renal cell carcinoma treatment (10 papers), Immunotherapy and Immune Responses (10 papers), Cancer Genomics and Diagnostics (8 papers) and Virus-based gene therapy research (6 papers). The work is most often cited by research in Oncology (1.0k citations), Immunology (394 citations) and Cancer Research (271 citations). Jie Dai has collaborated with scholars based in China, United States and Ethiopia. Frequent co-authors include Lu Si, Xinan Sheng, Chuanliang Cui, Jun Guo, Zhihong Chi, Yan Kong, Bin Lian, Xue Bai, Lili Mao and Tianxiao Xu. Their work appears in journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and ACS Nano.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact